Radioimmune assay of human platelet prostaglandin synthetase.
Normal platelet function depends, in part, on  platelet PG synthesis. PG synthetase (cyclo-oxygenase) catalyzes the first step in PG synthesis, the formation of PGH2 from arachidonic acid. Inhibition of the enzyme by ASA results in an abnormality in the platelet release reaction. Patients with apparent congenital abnormalities in the enzyme have been described, and the defects have been referred to as "aspirin-like" defects of platelet function. These patients lack platelet PG synthetase activity, but the actual content of PG synthetase protein in these individuals' platelets is unknown. Therefore an RIA for human platelet PG synthetase would provide new information, useful in assessing the aspirin-like defects of platelet function. An RIA for human platelet PG synthetase is described. The assay utilizes a rabbit antibody directed against the enzyme is assayed by its ability to inhibit precipitation of the [125I]antigen. The assay is sensitive to 1 ng of enzyme. By the immune assay, human platelets contain approximately 1200 ng of PG synthetase protein per 1.5 mg of platelet protein (approximately 10(9) platelets). This content corresponds to 10,000 enzyme molecules per platelet. The assay provides a rapid and convenient assay for the human platelet enzyme, and it can be applied to the assessment of patients with apparent platelet PG synthetase (cyclo-oxygenase) deficiency.
D001241:Aspirin / Q000009:adverse effects; D001791:Blood Platelet Disorders / Q000097:blood / Q000139:chemically induced / Q000175:diagnosis; D001792:Blood Platelets / Q000201:enzymology*; D004796:Clinical Enzyme Tests; D016861:Cyclooxygenase Inhibitors; D006801:Humans; D011451:Prostaglandin-Endoperoxide Synthases / Q000097:blood* / Q000172:deficiency; D011863:Radioimmunoassay / Q000379:methods*; D012016:Reference Values
D016861:Cyclooxygenase Inhibitors; D011451:Prostaglandin-Endoperoxide Synthases; D001241:Aspirin